7th septembre 2023
Actualités
Retrouvez tous nos derniers communiqués de presse. Restez informé des dernières actualités et des événements auxquels participe Curium.
15th août 2023
Curium announces achievement of co-primary endpoints in phase 2 of its phase 1/2 SOLAR clinical trial imaging men with histologically-proven prostate cancer using copper Cu 64 PSMA I&T
28th juillet 2023
Curium receives marketing authorization in the EU for Pylclari™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
25th juillet 2023
Curium announces license and development agreement with Lantheus for AI-based PSMA PET software in Europe
21st juillet 2023
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
21st juillet 2023
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
23rd mai 2023
Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T
2nd mai 2023
Curasight and Curium announce global partnership for uTRACE® in prostate cancer
14th mars 2023
Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial
2nd mars 2023
Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO
27th janvier 2023
Curium is attending these global congresses in 2023
21st décembre 2022
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
24th novembre 2022
Curium’s Customers to benefit from Mo-99 Production restart
22nd novembre 2022
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
9th novembre 2022
Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
18th août 2022
NRG and Curium Sign Multi-Year Isotope Production Contract
27th juin 2022
Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency
12th mai 2022
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
3rd mai 2022
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
19th avril 2022